Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Highland Copper Announces Updated Process Plant Flow Sheet Demonstrating Increased Copper Recoveries of 87.6% and Reduced Processing Costs

(NYSE:HI) VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Highland Copper Company Inc. (TSXV: HI; OTCQB: HDRSF) (“Highland” or the “Company”) is pleased to announce positive resul...

How does this new recovery rate compare to Highland’s historical performance and to peers in the sector, and what implications does it have for the project’s net‑present value and valuation? What is the expected timeline to implement the updated process plant flow sheet into the Copperwood project’s mining plan and capital‑expenditure schedule? How will the improved 87.6% copper recovery and lower processing costs affect Highland Copper’s cash‑flow projections and earnings guidance?
Symbol: HI
Mining
7 days ago
Read more globenewswire

TROX Investors Have Opportunity to Lead Tronox Holdings plc Securities Fraud Lawsuit with the Schall Law Firm

(NYSE:TROX) LOS ANGELES--(BUSINESS WIRE)---- $TROX--TROX Investors Have Opportunity to Lead Tronox Holdings plc Securities Fraud Lawsuit with the Schall Law Firm

What is the probability that the lawsuit will lead to a material stock price movement for TROX investors? How might the lawsuit affect Tronox Holdings’ potential financial liabilities and future earnings? What specific role can TROX investors play in leading the securities fraud lawsuit with Schall Law Firm?
Symbol: TROX
Lawsuits
7 days ago
Read more businesswire

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

(NASDAQ:GILD) FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Pla...

What are the potential risks and timelines related to regulatory approvals, manufacturing scale‑up, and pricing negotiations that could influence the long‑term performance of Gilead's HIV prevention portfolio? What is the competitive landscape for HIV PrEP injectables in low- and lower‑middle‑income markets, and how does lenacapavir compare to existing products like cabotegravir? How will the partnership with PEPFAR and the anticipated rollout of lenacapavir affect Gilead's revenue forecasts and stock valuation?
Symbol: GILD
Partnership
7 days ago
Read more businesswire